Efficacy and safety of Ozone Therapy for patients with chronic hepatitis B: A multicenter, randomized clinical trial

Hong Yu (禹弘), Pingyan Chen (陈平雁), Jilin Chen (陈计林), Wei Dai (戴炜), Zhimin Wu (吴志敏), Yabing Guo (郭亚兵)

Department of Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China.

ABSTRACT

Background
Ozone therapy has a long history. Some studies proved that ozone therapy was useful in treatment of virus hepatitis.

Objective
To evaluate the efficacy and safety of new medical ozone therapy system for the treatment of chronic hepatitis B.

Method
One hundred eighty-nine patients with chronic hepatitis B were included in this open-label, phase 3 study, and randomly assigned to receive ozone autohemotherapy with experimental ozone generator TianYi (group 1) or with ozone generator Humares (group 2) or oral diammonium glycyrrhizinate capsules (group 3) in a 1:1:1 ratio for 12 weeks. The primary efficacy end point was sera HBV DNA level of less than 1 × 10^3 IU/ml or having a more than 2 log10 reduction in HBV DNA level at the end of 12 weeks treatment as compared to baseline HBV DNA level. Secondary end points included HBeAg seroconversion, biochemical response, and combined response.

Results
At the end of 12 weeks treatment, the proportion of patients reached the primary end point of virologic response in group 1, group 2, and group 3 were 22.4% (13/58, 95% CI, 12.5 to 35.3), 14.7 (9/61, 95% CI, 7.0 to 26.2) and 3.9% (2/51, 95% CI, 0.5 to 13.5), respectively (p=0.021) in the pre-protocol population. Virologic response occurred in more patients receiving ozone therapy with experimental device than patients receiving oral diammonium glycyrrhizinate capsules (mean difference 18.5%, 95% CI 6.3 to 31.5, p=0.005). However, there was no statistical difference in VR12 rates between the treatment of medical ozone therapy system with experimental device (group 1) and with Humares (group 2) (mean difference 7.7%, 95% CI -6.5 to 22.0, p=0.282). More HBeAg seroconversion in patients treated by Tianyi ozone therapy system than those treated by Humares ozone therapy device and oral diammonium glycyrrhizinate capsules (14.8%, 5.1% and 7.3%, respectively, P = 0.272). Higher biochemical response rate was observed in patients receiving ozone therapy than oral diammonium glycyrrhizinate capsules (31.6%, 36.7% and 24.0%, respectively, p = 0.359). The safety profile was similar for the three treatment groups and adverse events were scare infrequent and mild.

DOI: 10.7203/jo3t.2.2.2018.11131
Conclusions

Ozone therapy had superior antiviral efficacy with a similar safety profile as compared with oral diammonium glycyr rhizinate capsules through week 12 treatment. Ozone therapy is also associated with normalized ALT and AST levels, demonstrating that ozone therapy could benefit the patients with chronic hepatitis B.